Get the Stockscreener App
1.50
3.45%
0.05
After Hours:
1.53
0.03
+2.00%
NanoViricides Inc stock is traded at $1.50, with a volume of 584.40K.
It is up +3.45% in the last 24 hours and up +4.17% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.45
Open:
$1.47
24h Volume:
584.40K
Relative Volume:
3.54
Market Cap:
$24.11M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.1429
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+9.49%
1M Performance:
+4.17%
6M Performance:
+12.78%
1Y Performance:
+0.67%
1-Day Range:
$1.45
$1.63
1-Week Range:
$1.30
$1.63
52-Week Range:
$0.94
$1.9195
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.50 | 25.27M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
How institutional ownership impacts NanoViricides Inc. stock2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - Norwich Bulletin
NanoViricides Advances Dual-Track Clinical Strategy for Broad-Spectrum Antiviral Drug Candidate NV-387 - citybuzz -
Identifying reversal signals in NanoViricides Inc.July 2025 Retail & Consistent Profit Trade Alerts - newser.com
Understanding NanoViricides Inc.’s price movementWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Detecting price anomalies in NanoViricides Inc. with AI2025 Volatility Report & Weekly Hot Stock Watchlists - newser.com
Phase II start by late CY25/early CY26: NanoViricides' NV-387 pursues MPox and broad respiratory virus trials - Stock Titan
Is NanoViricides Inc. stock ideal for retirement investorsJuly 2025 Review & Daily Chart Pattern Signals - newser.com
Nanoviricides: Dual track clinical development during 2026Preview | NYSE-A:NNVC - Proactive financial news
How NanoViricides Inc. (NV3P) stock trades after rate cutsMarket Volume Summary & Low Risk Profit Maximizing Plans - newser.com
News impact scoring models applied to NanoViricides Inc.July 2025 Final Week & Free Expert Approved Momentum Trade Ideas - newser.com
Can NanoViricides Inc. (NV3P) stock attract ESG investments2025 Price Targets & Capital Protection Trade Alerts - newser.com
Using data filters to optimize entry into NanoViricides Inc.Portfolio Update Report & Breakout Confirmation Trade Signals - newser.com
NanoViricides, Inc. Has Filed its Annual Report - The Daily Jeffersonian
Is NanoViricides Inc. stock in buy zone after pullbackMarket Activity Recap & Long-Term Growth Portfolio Plans - newser.com
Exit strategy if you’re trapped in NanoViricides Inc.Quarterly Earnings Summary & Short-Term High Return Strategies - newser.com
Why global investors buy NanoViricides Inc. stockTake Profit & Weekly Breakout Watchlists - newser.com
Is NanoViricides Inc. (NV3P) stock a safe buy pre earnings2025 Winners & Losers & Free Safe Capital Growth Stock Tips - newser.com
Using Bollinger Bands to evaluate NanoViricides Inc.July 2025 Review & Reliable Price Breakout Alerts - newser.com
How to read the order book for NanoViricides Inc.2025 Volatility Report & Daily Oversold Bounce Ideas - newser.com
Is NanoViricides Inc. (NV3P) stock undervalued by metricsExit Point & Risk Controlled Swing Alerts - newser.com
Trend analysis for NanoViricides Inc. this weekPortfolio Value Report & Safe Entry Momentum Tips - newser.com
NanoViricides Inc (AMEX: NNVC) stock has achieved $1.4600 in the past week - fostersleader.com
What makes NanoViricides Inc. stock appealing to growth investorsJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):